권호기사보기
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
---|---|---|---|---|---|---|---|---|---|
연구/단체명을 입력해주세요. |
|
|
|
|
|
* 주제를 선택하시면 검색 상세로 이동합니다.
Background: Voglibose is an α-glucosidase inhibitor. The purpose of this study was to evaluate the pharmacodynamic characteristics of voglibose for determining the appropriate study design and parameters for a pharmacodynamic equivalence study of voglibose.
Methods: This study consisted of two studies. The single dose study had an open and single sequence design. Nineteen subjects received placebo and then one tablet of voglibose on two consecutive days with sucrose. The multiple dose study was performed with the similar design, except that it was a multiple dose of the single dose study. Nine subjects who showed an effective response in the single dose study received placebo three times and then voglibose 4 times on two consecutive days. Serial blood samples for pharmacodynamic parameters were taken until 180 mins after each administration. The baseline adjusted maximum serum glucose level (Gmax) and area under the serum glucose level-time profiles were determined and compared.
Results: In the single dose study, the difference in Gmax was -10.6 ± 28.7 mg/dL. The area under the serum glucose concentration-time curve (AUGC0-1h) of placebo and voglibose were 7825.0 ± 1145.3 mg.min/dL, 7907.5 ± 917.2 mg.min/dL, respectively. In the multiple dose study, the difference in Gmax was 46.6 ± 16.1 mg/dL. The AUGC0-1h of placebo and voglibose were 8138.6 ± 721.9 mg.min/dL and 6499.7 ± 447.2 mg.min/dL, respectively. The Gmax and AUGC0-1h of the multiple dose study was significantly different between placebo and voglibose in paired t-test.
Conclusion: The differences in Gmax and AUGC0-1h are suitable for pharmacodynamic parameters to evaluate bioequivalence of voglibose.
기사명 | 저자명 | 페이지 | 원문 | 목차 |
---|---|---|---|---|
보글리보스 제제인 보글리정의 베이슨정에 대한 약력학 특성 비교 | 김미조 | pp.34-40 |
|
|
건강한 남성 자원자에서 실데나필 제제인 플리즈구강용해필름과 비아그라®의 약동학적 특성 및 안전성의 비교평가 | 홍태곤 | pp.26-33 |
|
|
대한임상약리학회지의 발전 방안 | 임영채 | pp.5-16 |
|
|
순환계용약 및 기타 효능군의 성분별 생물학적동등성시험 권고사항 마련 | 배수현, 배수경 | pp.17-25 |
|
|
건강한 자원자에서 무르페® 패치와 트라스트® 패치 투여 시 약동학적 특성 및 피부자극성을 비교 평가하기 위한 무작위배정, 공개, 2-Way 교차 임상 연구 | 최윤정 | pp.41-51 |
|
|
건강한 한국인에서 Zofenopril의 약동/약력학적 특성 및 내약성에 관한 무작위, 위약대조, 이중맹검, 평행군, 반복투여, 단계적 증량 임상연구 | 오재성 | pp.52-62 |
|
|
국내 의약품 임상시험 실시기관에서의 임상시험 관리약국 운용 현황 | 장유정 | pp.71-81 |
|
|
건강한 한국인 자원자에서 보글리보스 제제의 약효 동등성 평가 항목 선정을 위한 위약 대조, 단회 및 반복 투여 후 약력학 특성 비교 임상시험 | 장경호 | pp.63-70 |
|
번호 | 참고문헌 | 국회도서관 소장유무 |
---|---|---|
1 | The present state of diabetes mellitus in Korea | 소장 |
2 | Monnier, L., Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest, 2000;30(2):3-11. | 미소장 |
3 | [alpha-Glucosidase inhibitor]. ![]() |
미소장 |
4 | Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance ![]() |
미소장 |
5 | KFDA, KFDA web sites on Bioequivalence test information.http://drug.mfds.go.kr/html/men uLinkBody.jsp?p_menuId=0201#1. [Online] (last visited 01 May 2013). | 미소장 |
6 | Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. ![]() |
미소장 |
7 | The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. ![]() |
미소장 |
8 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations, 2003. | 미소장 |
9 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Draft Guidance on Acarbose. 2009. | 미소장 |
10 | Methods for Pharmacodynamic Analysis and Proposed Protocols for Bioequivalence Study of Acarbose | 소장 |
11 | Min Zhang, Jin Yang, Lei Tao, Lingjun Li, Pengcheng Ma, John Paul Fawcett. Acarbose Bioequivalence: Exploration of New Pharmaco- dynamic Parameters. AAPS J, 2012;14(2):345- 351. | 미소장 |
12 | Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets. ![]() |
미소장 |
13 | Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Thera, 1997;19(4):720-729. | 미소장 |
14 | Comparison of the effects of acarbose and voglibose on plasma glucose, endogenous insulin sparing, and gastrointestinal adverse events in obese subjects: a randomized, placebo-controlled, double-blind, three-way crossover study ![]() |
미소장 |
15 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (Draft). 2008. | 미소장 |
16 | Practical Diabetes Care. By David Levy. 3rd Edition Published by Wiley-Blackwell, 2011 Paperback, price: ISBN: 978 1 4443 3385 5 Website ![]() |
미소장 |
*표시는 필수 입력사항입니다.
*전화번호 | ※ '-' 없이 휴대폰번호를 입력하세요 |
---|
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
---|
도서위치안내: / 서가번호:
우편복사 목록담기를 완료하였습니다.
*표시는 필수 입력사항입니다.
저장 되었습니다.